PhRMA
MAY 22, 2023
As we’ve discussed on this blog before, the U.S. Food and Drug Administration’s (FDA) accelerated approval program has served as a critical lifeline for patients with serious and life-threatening conditions. The program was originally established at the urging of patient advocates during the height of the HIV/AIDS epidemic, in which patients waited years for the FDA to review and approve new treatments.
Pharmacy Times
MAY 24, 2023
Specialty pharmacists—those caring for patients with serious, sometimes life-threatening conditions such as cancer or rheumatologic disease—are not immune from the ongoing labor crisis.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
MAY 24, 2023
The attitudes of community-based opioid use disorder treatment center staff toward the emergency department as a site of initiation were varied, with some feeling that emergency department-initiated buprenorphine may attract patients who were not experiencing life-threatening emergencies.
Pharmacy Is Right For Me
MAY 22, 2023
Jamila Jorden, a pharmacist and academic advisor, recently gave an interview discussing the multifaceted role of pharmacists. She also discussed the importance of experiential education in preparing pharmacy students for their careers. Jamila’s experiences in the pharmacy profession provide valuable insight into the varied roles and responsibilities of pharmacists.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
MAY 25, 2023
Iowa's Department of Health and Human Services, which manages the two health insurers that delivered care to adults and children in the state’s Medicaid program last year, was alleged to provide inadequate mental and behavioral health care to children on Medicaid.
STAT
MAY 24, 2023
Over the last few years, Daniel Cleggett Jr. appeared to be living a charmed life. The founder of a small Boston-area addiction treatment empire knew he was under scrutiny; the Globe and STAT News published investigations in 2017 and 2019 into his questionable business dealings, and the Massachusetts attorney general’s office announced shortly after that it was examining alleged scams involving addiction treatment.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
European Pharmaceutical Review
MAY 23, 2023
New research by IQVIA and recently published in the 2023 Swiss Biotech Report shows that 20 percent of European biotech companies are now headquartered in Switzerland. Sixty three out of a total of 265 companies settling in Switzerland were biotechs. This makes it the second most important sector after ICT, the research found. 2022 statistics by the Swiss federal government confirm that the trend to base here is continuing.
Drug Topics
MAY 24, 2023
The antibiotic, marketed as Xacduro, is indicated for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii.
STAT
MAY 23, 2023
In 2023, just under 2 million Americans will be diagnosed with cancer. Many will endure multiple CT and MRI studies and intensive medical care, including surgery, radiation, chemotherapy, or immunotherapy. Fortunately, advances in treatment and novel therapies have steadily improved survival following a cancer diagnosis. Cancer death rates have declined by 27% over the past 20 years.
Pharmacy Times
MAY 22, 2023
Supportive nurse managers and supervisors as well as nurses’ involvement in organizational governance may help lower hospital-onset Clostridioides difficile infection in acute care hospitals.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
PharmExec
MAY 22, 2023
The market for prescription medicines in the United States was subject to major shifts in use across therapeutic areas in 2022, reflecting changes in patient health needs, the development, and availability of novel medicines, and complex market dynamics.
Drug Topics
MAY 22, 2023
The approval of Rinvoq (upadacitinib) was based on the results of three clinical trials: two induction therapy studies and one maintenance study.
STAT
MAY 23, 2023
Health care companies are racing to incorporate generative AI tools into their product pipelines and IT systems after the technology displayed an ability to perform many tasks faster, cheaper — and sometimes better — than humans. But the rush to harness the power of so-called large language models, which are trained on vast troves of data, is outpacing efforts to assess their value.
Pharmacy Times
MAY 23, 2023
In neonatal intensive care units, probiotic usage was associated with a decline in necrotizing enterocolitis, but not with sepsis or mortality rates.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmaceutical Technology
MAY 22, 2023
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted an investigational new drug application (IND) for SinoMab BioScience’s SM17 to treat asthma. SM17 is a humanised IgG4-k monoclonal antibody that targets IL-17RB to treat asthma, idiopathic pulmonary fibrosis (IPF), atopic dermatitis (AD) and other immunological disorders.
Drug Topics
MAY 24, 2023
Data presented at Digestive Disease Week show that patients with IBD had less intense post-vaccination symptoms after a fourth dose.
STAT
MAY 24, 2023
Every day, it seems, is mental health awareness day. In the U.S., there’s Eating Disorders Awareness Week in February. May is National Mental Health Awareness Month, which includes National Children’s Mental Health Awareness Day. September is Suicide Prevention Awareness Month and in October we go global, with World Mental Health Day.
Pharmacy Times
MAY 26, 2023
Candace Cotto, RN, reviews the process of incorporating fecal microbiota, live-jslm treatment into clinical practice, what patients can expect, and the room sanitation process after the procedure.
European Pharmaceutical Review
MAY 26, 2023
The UK Chancellor has announced a £650 million life sciences growth package (Life Sci for Growth) to help deliver the Science and Technology framework through reforming regulation, boosting investment and driving up talent and skills. Bringing together 10 different policies, the package includes: A total of £121 million to improve commercial clinical trials to bring new medicines to patients faster Up to £48 million of new money for scientific innovation to prepare for any future health emergenc
Drug Topics
MAY 25, 2023
A short supply of cisplatin and carboplatin is forcing health care providers to find less effective alternative treatments.
Pharmaceutical Technology
MAY 26, 2023
The US Food and Drug Administration (FDA) has granted priority review for Takeda and HUTCHMED’s new drug application (NDA) for fruquintinib. Fruquintinib is a selective and potent oral VEGFR -1, -2 and -3 receptors inhibitor and is used for the treatment of adults with previously treated metastatic colorectal cancer. Fruquintinib will be the first and only highly selective inhibitor of these receptors approved in the US.
Pharmacy Times
MAY 25, 2023
Women with recurrent urinary tract infections (UTIs) are often on and off antibiotics for years, and even decades, as the only treatment available in health systems for treating UTIs.
European Pharmaceutical Review
MAY 24, 2023
The US Food and Drug Administration (FDA) has approved the first-ever redosable gene therapy for the rare skin disease dystrophic epidermolysis bullosa (DEB). VYJUVEK (beremagene geperpavec-svdt) is authorised for DEB patients six months of age or older. The gene therapy is a topical gel that restores functional copies of the COL7A1 gene to provide wound healing and sustained functional COL7 protein expression with redosing.
Drug Topics
MAY 24, 2023
Researchers found an increased occurrence of CDI in individuals who were prescribed antidepressants.
Pharmaceutical Technology
MAY 26, 2023
The immuno-oncology market continues to evolve as treatments establish their presence across different types of cancer, having seen approvals in multiple indications in the past decade. While the market was worth over $6 billion in 2012, this has now grown to nearly $48 billion only a decade later, said Avigayil Chalk, PhD, GlobalData’s Senior Oncology and Haematology analyst, at an immuno-oncology webinar held on May 23.
Pharmacy Times
MAY 23, 2023
A barrier in effectively treating HIV has been the latency of infected CD4+ T cells, which are often treatment-resistant and contribute to the persistence nature of the virus.
Fierce Healthcare
MAY 24, 2023
Startup Florence acquires Zipnosis from Bright Health to build out telehealth services hlandi Wed, 05/24/2023 - 06:15
Drug Topics
MAY 26, 2023
More than 11.6 million treatment courses of the medication have been prescribed in the U.S. to date.
Pharmaceutical Technology
MAY 26, 2023
Krystal Biotech has received approval from the US Food and Drug Administration for topical gene therapy VYJUVEK to treat dystrophic epidermolysis bullosa (DEB) in adults and in children aged six months and above. VYJUVEK is designed to address the underlying genetic cause of the disease. An excipient gel applied topically is a key component of the therapy, which is supplied by Krystal’s client, Berkshire Sterile Manufacturing (BSM).
Pharmacy Times
MAY 23, 2023
Anne Cassity, JD, senior vice president of Public Affairs at the National Community Pharmacists Association discusses congressional and lawmaker trends on pharmacy benefits manager reform with guests, Adam Harbison and Kaite Krell.
STAT
MAY 26, 2023
When a new and hoped-to-be safer oral polio vaccine started to make its way into use in March 2021, there was huge optimism that this long-needed tool would help the polio eradication campaign quell a growing problem that was — and is still — complicating efforts to stamp out polio forever. Two years later, expectations surrounding the new vaccine, known as novel oral polio vaccine type 2, or nOPV2 for short, are moderating a bit.
Drug Topics
MAY 22, 2023
Active tobacco use and BMI were inversely related to the risk of developing IPD.
Pharmaceutical Technology
MAY 25, 2023
Appili Therapeutics has received a US patent for ATI-1501 , a liquid oral reformulation of metronidazole. The patent claims for ATI-1501 were published by the US patent and trademark office under US application no. 18/072,154, filed on 30 November 2022. It covers the composition and preparation methods for ATI-1501 until 2039. Metronidazole is a widely used frontline oral treatment for parasitic and anaerobic bacterial infections.
Pharmacy Times
MAY 25, 2023
Structural inequalities that contribute to HIV acquisition are known to also contribute to housing stability, and this was apparent in findings regarding race and ethnicity.
Expert insights. Personalized for you.
209 
Let's personalize your content